The microbiome-lymphoma Axis: A systematic review and Meta-analysis of gut Dysbiosis pattern in diffuse large B-cell lymphoma

<h3>Background</h3><p dir="ltr">Gut microbiota has emerged as a critical mediator of immune homeostasis and cancer biology. Increasing evidence suggests that gut dysbiosis may play a significant role in the pathogenesis of diffuse large B-cell lymphoma (DLBCL), the most c...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Sarah A. Elkourashy (21632903) (author)
مؤلفون آخرون: Rasha Abu-El-Ruz (10650680) (author), Medhat Z. Askar (22564124) (author), Ahmad Hamdan (332542) (author), Susu M. Zughaier (14151987) (author)
منشور في: 2025
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513532728442880
author Sarah A. Elkourashy (21632903)
author2 Rasha Abu-El-Ruz (10650680)
Medhat Z. Askar (22564124)
Ahmad Hamdan (332542)
Susu M. Zughaier (14151987)
author2_role author
author
author
author
author_facet Sarah A. Elkourashy (21632903)
Rasha Abu-El-Ruz (10650680)
Medhat Z. Askar (22564124)
Ahmad Hamdan (332542)
Susu M. Zughaier (14151987)
author_role author
dc.creator.none.fl_str_mv Sarah A. Elkourashy (21632903)
Rasha Abu-El-Ruz (10650680)
Medhat Z. Askar (22564124)
Ahmad Hamdan (332542)
Susu M. Zughaier (14151987)
dc.date.none.fl_str_mv 2025-10-30T09:00:00Z
dc.identifier.none.fl_str_mv 10.1016/j.blre.2025.101341
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/The_microbiome-lymphoma_Axis_A_systematic_review_and_Meta-analysis_of_gut_Dysbiosis_pattern_in_diffuse_large_B-cell_lymphoma/30540041
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Immunology
Oncology and carcinogenesis
Gut microbiota
Diffuse large B-cell lymphoma
Non-Hodgkin lymphoma
Dysbiosis
Lymphomagenesis
Immune modulation
Microbiome-targeted therapy
dc.title.none.fl_str_mv The microbiome-lymphoma Axis: A systematic review and Meta-analysis of gut Dysbiosis pattern in diffuse large B-cell lymphoma
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <h3>Background</h3><p dir="ltr">Gut microbiota has emerged as a critical mediator of immune homeostasis and cancer biology. Increasing evidence suggests that gut dysbiosis may play a significant role in the pathogenesis of diffuse large B-cell lymphoma (DLBCL), the most common and aggressive subtype of non-Hodgkin lymphoma (NHL). However, a comprehensive synthesis of the microbial alterations associated with DLBCL remains poorly defined. </p><h3>Methods</h3><p dir="ltr">We systematically reviewed and meta-analyzed thirteen studies (<i>n</i> = 4087 cases) to assess gut microbiota alterations in DLBCL. Both observational and Mendelian randomization designs were included. Pooled odds ratios (OR) were calculated for mendelian randomization studies using random-effects models, and microbial shifts were analyzed at the species level to contextualize biological relevance. Observational studies were used for qualitative assessment.</p><h3>Results</h3><p dir="ltr">Meta analysis was done for the mendelian randomization studies (<i>n</i> = 3737 cases). The overall pooled OR was 0.96 (95 % CI: 0.93–1.00), suggested a slight shift towards depletion, with considerable heterogeneity (I<sup>2</sup> = 78.7 %). Species-level analysis revealed significant enrichment of pro-inflammatory or potentially oncogenic taxa in DLBCL, including Bilophila (OR = 1.78), Desulfovibrionaceae (OR = 1.58), and Coprobacter (OR = 1.37). Conversely, beneficial commensals with anti-inflammatory and metabolic regulatory roles such as <i>Eubacterium coprostanoligenes</i> group (OR = 0.19), Alistipes (OR = 0.57), <i>Ruminococcaceae</i> UCG011 (OR = 0.75) were significantly depleted. </p><h3>Conclusions</h3><p dir="ltr">This first comprehensive synthesis demonstrates a reproducible species-level microbial signature in DLBCL, characterized by depletion of protective commensals and enrichment of pro-tumorigenic taxa. Mechanistically, these shifts may promote lymphomagenesis via inflammatory, metabolic, and immune-modulatory pathways. Our findings highlight the gut microbiota as a latent biomarker source and therapeutic target, supporting microbiota-modulating strategies in precision lymphoma care.</p><h2>Other Information</h2><p dir="ltr">Published in: Blood Reviews<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.blre.2025.101341" target="_blank">https://dx.doi.org/10.1016/j.blre.2025.101341</a></p>
eu_rights_str_mv openAccess
id Manara2_5401e47357b626dfda9684e04f515475
identifier_str_mv 10.1016/j.blre.2025.101341
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/30540041
publishDate 2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling The microbiome-lymphoma Axis: A systematic review and Meta-analysis of gut Dysbiosis pattern in diffuse large B-cell lymphomaSarah A. Elkourashy (21632903)Rasha Abu-El-Ruz (10650680)Medhat Z. Askar (22564124)Ahmad Hamdan (332542)Susu M. Zughaier (14151987)Biomedical and clinical sciencesImmunologyOncology and carcinogenesisGut microbiotaDiffuse large B-cell lymphomaNon-Hodgkin lymphomaDysbiosisLymphomagenesisImmune modulationMicrobiome-targeted therapy<h3>Background</h3><p dir="ltr">Gut microbiota has emerged as a critical mediator of immune homeostasis and cancer biology. Increasing evidence suggests that gut dysbiosis may play a significant role in the pathogenesis of diffuse large B-cell lymphoma (DLBCL), the most common and aggressive subtype of non-Hodgkin lymphoma (NHL). However, a comprehensive synthesis of the microbial alterations associated with DLBCL remains poorly defined. </p><h3>Methods</h3><p dir="ltr">We systematically reviewed and meta-analyzed thirteen studies (<i>n</i> = 4087 cases) to assess gut microbiota alterations in DLBCL. Both observational and Mendelian randomization designs were included. Pooled odds ratios (OR) were calculated for mendelian randomization studies using random-effects models, and microbial shifts were analyzed at the species level to contextualize biological relevance. Observational studies were used for qualitative assessment.</p><h3>Results</h3><p dir="ltr">Meta analysis was done for the mendelian randomization studies (<i>n</i> = 3737 cases). The overall pooled OR was 0.96 (95 % CI: 0.93–1.00), suggested a slight shift towards depletion, with considerable heterogeneity (I<sup>2</sup> = 78.7 %). Species-level analysis revealed significant enrichment of pro-inflammatory or potentially oncogenic taxa in DLBCL, including Bilophila (OR = 1.78), Desulfovibrionaceae (OR = 1.58), and Coprobacter (OR = 1.37). Conversely, beneficial commensals with anti-inflammatory and metabolic regulatory roles such as <i>Eubacterium coprostanoligenes</i> group (OR = 0.19), Alistipes (OR = 0.57), <i>Ruminococcaceae</i> UCG011 (OR = 0.75) were significantly depleted. </p><h3>Conclusions</h3><p dir="ltr">This first comprehensive synthesis demonstrates a reproducible species-level microbial signature in DLBCL, characterized by depletion of protective commensals and enrichment of pro-tumorigenic taxa. Mechanistically, these shifts may promote lymphomagenesis via inflammatory, metabolic, and immune-modulatory pathways. Our findings highlight the gut microbiota as a latent biomarker source and therapeutic target, supporting microbiota-modulating strategies in precision lymphoma care.</p><h2>Other Information</h2><p dir="ltr">Published in: Blood Reviews<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.blre.2025.101341" target="_blank">https://dx.doi.org/10.1016/j.blre.2025.101341</a></p>2025-10-30T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.blre.2025.101341https://figshare.com/articles/journal_contribution/The_microbiome-lymphoma_Axis_A_systematic_review_and_Meta-analysis_of_gut_Dysbiosis_pattern_in_diffuse_large_B-cell_lymphoma/30540041CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/305400412025-10-30T09:00:00Z
spellingShingle The microbiome-lymphoma Axis: A systematic review and Meta-analysis of gut Dysbiosis pattern in diffuse large B-cell lymphoma
Sarah A. Elkourashy (21632903)
Biomedical and clinical sciences
Immunology
Oncology and carcinogenesis
Gut microbiota
Diffuse large B-cell lymphoma
Non-Hodgkin lymphoma
Dysbiosis
Lymphomagenesis
Immune modulation
Microbiome-targeted therapy
status_str publishedVersion
title The microbiome-lymphoma Axis: A systematic review and Meta-analysis of gut Dysbiosis pattern in diffuse large B-cell lymphoma
title_full The microbiome-lymphoma Axis: A systematic review and Meta-analysis of gut Dysbiosis pattern in diffuse large B-cell lymphoma
title_fullStr The microbiome-lymphoma Axis: A systematic review and Meta-analysis of gut Dysbiosis pattern in diffuse large B-cell lymphoma
title_full_unstemmed The microbiome-lymphoma Axis: A systematic review and Meta-analysis of gut Dysbiosis pattern in diffuse large B-cell lymphoma
title_short The microbiome-lymphoma Axis: A systematic review and Meta-analysis of gut Dysbiosis pattern in diffuse large B-cell lymphoma
title_sort The microbiome-lymphoma Axis: A systematic review and Meta-analysis of gut Dysbiosis pattern in diffuse large B-cell lymphoma
topic Biomedical and clinical sciences
Immunology
Oncology and carcinogenesis
Gut microbiota
Diffuse large B-cell lymphoma
Non-Hodgkin lymphoma
Dysbiosis
Lymphomagenesis
Immune modulation
Microbiome-targeted therapy